Integra Buys Acclarent From J&J To Expand ENT 'Footprint'

Integra will pay $275m in cash plus $5m more in potential milestone incentive payments to add Acclarent’s ear, nose, and throat surgery devices to its existing neurosurgery portfolio.

The acquisition deal will double the size of Sosei Group.
• Source: Shutterstock

[Editor’s Note: This article was updated on 14 December with additional commentary from securities analysts that arrived after publication of the original version on 13 December.]

Integra LifeSciences has agreed to acquire Acclarent from Johnson & Johnson/Ethicon, adding Acclarent’s ear, nose, and throat surgery (ENT) product lines to the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business